News
-
-
-
-
-
-
PRESS RELEASE
Launch of a capital increase with an indicative amount of approximately EUR10 million to accelerate commercial development
Fermentalg announces a capital increase of approximately €10 million to accelerate commercial development. Major shareholder Huvepharma and institutional investors show strong support. Price per share: €0.46, 20% discount to reference price -
-
-
-
PRESS RELEASE
Success of the sales diversification strategy in the first quarter of 2026 and commercial launches of the new BioSolutions
Fermentalg achieves record turnover of €3.7 million in Q1 2026, with 42% sales growth excluding aquaculture. Positive outlook with rising fish oil prices and upcoming product launches